Gowling WLG advised NurExone on the private placement. NurExone Biologic Inc., a biopharmaceutical company pioneering the development of non-invasive ExoTherapy for treating traumatic spinal cord injuries,...
NurExone Biologic’s $2m Private Placement
NurExone Biologic Inc.’s Reverse Takeover Transaction
Gowling WLG advised NurExone Biologic Ltd. on the deal. NurExone Biologic Inc. (formerly, EnerSpar Corp.) (TSXV: NRX) (the “Company”) announced that it had completed its previously...